MA27524A1 - Derives de 1-acyl-pyrrolidine destines au traitement d'infections virales - Google Patents

Derives de 1-acyl-pyrrolidine destines au traitement d'infections virales

Info

Publication number
MA27524A1
MA27524A1 MA28263A MA28263A MA27524A1 MA 27524 A1 MA27524 A1 MA 27524A1 MA 28263 A MA28263 A MA 28263A MA 28263 A MA28263 A MA 28263A MA 27524 A1 MA27524 A1 MA 27524A1
Authority
MA
Morocco
Prior art keywords
alkyl
treatment
acyl
aryl
viral infections
Prior art date
Application number
MA28263A
Other languages
English (en)
French (fr)
Inventor
Haigh David
David Hartley Charles
David Howes Peter
Lynette Jackson Deborah
Shah Pritom
John Slater Martin
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0224774A external-priority patent/GB0224774D0/en
Priority claimed from GB0229470A external-priority patent/GB0229470D0/en
Priority claimed from GB0317141A external-priority patent/GB0317141D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of MA27524A1 publication Critical patent/MA27524A1/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
MA28263A 2002-10-24 2005-05-06 Derives de 1-acyl-pyrrolidine destines au traitement d'infections virales MA27524A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0224774A GB0224774D0 (en) 2002-10-24 2002-10-24 Compounds
GB0229470A GB0229470D0 (en) 2002-12-18 2002-12-18 Compounds
GB0317141A GB0317141D0 (en) 2003-07-22 2003-07-22 Compounds

Publications (1)

Publication Number Publication Date
MA27524A1 true MA27524A1 (fr) 2005-09-01

Family

ID=32180212

Family Applications (1)

Application Number Title Priority Date Filing Date
MA28263A MA27524A1 (fr) 2002-10-24 2005-05-06 Derives de 1-acyl-pyrrolidine destines au traitement d'infections virales

Country Status (18)

Country Link
US (1) US7304087B2 (https=)
EP (1) EP1554274B1 (https=)
JP (1) JP2006506455A (https=)
KR (1) KR20050057670A (https=)
AR (1) AR041816A1 (https=)
AT (1) ATE418554T1 (https=)
AU (1) AU2003276172A1 (https=)
BR (1) BR0315417A (https=)
CA (1) CA2503471A1 (https=)
CO (1) CO5550450A2 (https=)
DE (1) DE60325498D1 (https=)
IS (1) IS7851A (https=)
MA (1) MA27524A1 (https=)
MX (1) MXPA05004435A (https=)
NO (1) NO20052472L (https=)
PL (1) PL376454A1 (https=)
TW (1) TW200418848A (https=)
WO (1) WO2004037818A1 (https=)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0304494D0 (en) * 2003-02-27 2003-04-02 Glaxo Group Ltd Compounds
GB0408995D0 (en) * 2004-04-22 2004-05-26 Glaxo Group Ltd Compounds
GB0423673D0 (en) * 2004-10-25 2004-11-24 Glaxo Group Ltd Compounds
GB0423672D0 (en) * 2004-10-25 2004-11-24 Glaxo Group Ltd Compounds
WO2006050035A1 (en) 2004-10-29 2006-05-11 Schering Corporation Substituted 5-oxo pyrazoles and [1,2,4]triazoles as antiviral agents
GB0519488D0 (en) * 2005-09-23 2005-11-02 Glaxo Group Ltd Compounds
GB0519478D0 (en) * 2005-09-23 2005-11-02 Glaxo Group Ltd Compounds
GB0519485D0 (en) * 2005-09-23 2005-11-02 Glaxo Group Ltd Compounds
GB0519486D0 (en) * 2005-09-23 2005-11-02 Glaxo Group Ltd Compounds
JP2010520200A (ja) 2007-02-28 2010-06-10 クオナトウス ファーマシューティカルズ,インコーポレイテッド 特定のマトリックスメタロプロテイナーゼ(mmp)阻害剤を使用する肝疾患を治療する方法
EP2142215B1 (en) 2007-05-04 2012-03-07 Vertex Pharmceuticals Incorporated Combination therapy for the treatment of hcv infection
US20090053175A1 (en) * 2007-08-24 2009-02-26 Yat Sun Or Substitute pyrrolidine derivatives
CN104710365A (zh) 2008-04-28 2015-06-17 旭化成制药株式会社 苯丙酸衍生物及其用途
UA103195C2 (uk) 2008-08-11 2013-09-25 Глаксосмитклайн Ллк Похідні пурину для застосування у лікуванні алергій, запальних та інфекційних захворювань
BRPI0917013A2 (pt) 2008-08-11 2016-02-16 Glaxosmithkline Llc métodos para tratar doenças alérgicas e outras condições inflamatórias, e para tratar ou prevenir doença, composto, composição farmacêutica, e, uso de um composto
BRPI0917458A2 (pt) 2008-08-11 2015-12-01 Glaxosmithkline Llc composto, método de tratamento de doenças e condições, composição farmacêutica, método para tratar ou prevenir doença, e, uso de um composto
WO2011098451A1 (en) 2010-02-10 2011-08-18 Glaxosmithkline Llc Purine derivatives and their pharmaceutical uses
DK2534149T3 (da) 2010-02-10 2015-01-05 Glaxosmithkline Llc 6-amino-2-{ [ (1s)-1-methylbutyl]oxy}-9-[5-(1-piperidinyl)pentyl]-7,9-dihydro-8h-purin-8-on-maleat
US9340530B2 (en) 2012-03-06 2016-05-17 Merck Sharp & Dohme Corp. Preparation and use of bicyclic himbacine derivatives as PAR-1 receptor antagonists
KR20160124157A (ko) 2014-02-20 2016-10-26 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 인간 인터페론의 유도인자로서의 피롤로[3,2]피리미딘 유도체
MX2017006302A (es) 2014-11-13 2018-02-16 Glaxosmithkline Biologicals Sa Derivados de adenina que son utiles en el tratamiento de enfermedades alergicas u otras afecciones inflamatorias.
CN107849084B (zh) 2015-12-03 2021-09-14 葛兰素史密斯克莱知识产权发展有限公司 作为sting调节剂的环状嘌呤二核苷酸
JP2019510802A (ja) 2016-04-07 2019-04-18 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited タンパク質調節物質として有用な複素環アミド
PT3440076T (pt) 2016-04-07 2022-07-29 Glaxosmithkline Ip Dev Ltd Amidas heterocíclicas úteis como modeladores de proteína
AU2018344902B2 (en) 2017-10-05 2021-06-03 Glaxosmithkline Intellectual Property Development Limited Modulators of stimulator of interferon genes (STING) useful in treating HIV
CA3077337A1 (en) 2017-10-05 2019-04-11 Glaxosmithkline Intellectual Property Development Limited Modulators of stimulator of interferon genes (sting)
GB201807924D0 (en) 2018-05-16 2018-06-27 Ctxt Pty Ltd Compounds
US20220227761A1 (en) 2019-05-16 2022-07-21 Stingthera, Inc. Oxoacridinyl acetic acid derivatives and methods of use
WO2020232378A1 (en) 2019-05-16 2020-11-19 Silicon Swat, Inc. Benzo[b][1,8]naphthyridine acetic acid derivatives and methods of use
GB201910305D0 (en) 2019-07-18 2019-09-04 Ctxt Pty Ltd Compounds
GB201910304D0 (en) 2019-07-18 2019-09-04 Ctxt Pty Ltd Compounds
EP4077318B1 (en) 2019-12-18 2025-10-15 Ctxt Pty Ltd Benzimidazole dimers as modulators of sting

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5977075A (en) 1995-04-21 1999-11-02 Novartis Ag N-aroylamino acid amides as endothelin inhibitors
AU1804299A (en) 1997-12-08 1999-06-28 Glycomed Incorporated Sialyl lewis x and sialyl lewis a glycomimetics
DE69938493T2 (de) 1998-01-26 2009-05-20 Massachusetts Institute Of Technology, Cambridge Endoskop zur erfassung von fluoreszenzbilder
CN1328546A (zh) 1998-04-23 2001-12-26 艾博特公司 作为神经氨酸酶抑制剂的吡咯烷
US6323180B1 (en) 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
EP1118287B1 (de) * 2000-01-21 2004-11-24 Alois Ing. Sampl Steckbares Regalsystem
US6713502B2 (en) * 2000-05-05 2004-03-30 Smithkline Beecham Corporation Anti-infectives
EP1339708A2 (en) 2000-11-20 2003-09-03 Scios Inc. Indole-type inhibitors of p38 kinase
JP2005511574A (ja) 2001-10-26 2005-04-28 ファルマシア アンド アップジョン カンパニー リミティド ライアビリティー カンパニー Nachrアゴニストとしてのn−アザビシクロ−置換ヘテロ二環式カルボキサミド
WO2003037893A1 (en) 2001-11-02 2003-05-08 Glaxo Group Limited Acyl dihydro pyrrole derivatives as hcv inhibitors
AU2002335950A1 (en) 2002-10-28 2004-05-13 Marquage Antivol Sherlock, Inc. Method of preventing theft of vehicles using intensive marking

Also Published As

Publication number Publication date
US20060258720A1 (en) 2006-11-16
AR041816A1 (es) 2005-06-01
ATE418554T1 (de) 2009-01-15
DE60325498D1 (de) 2009-02-05
JP2006506455A (ja) 2006-02-23
EP1554274B1 (en) 2008-12-24
NO20052472L (no) 2005-05-23
MXPA05004435A (es) 2005-07-26
CO5550450A2 (es) 2005-08-31
US7304087B2 (en) 2007-12-04
KR20050057670A (ko) 2005-06-16
PL376454A1 (en) 2005-12-27
BR0315417A (pt) 2005-08-16
AU2003276172A1 (en) 2004-05-13
EP1554274A1 (en) 2005-07-20
WO2004037818A1 (en) 2004-05-06
TW200418848A (en) 2004-10-01
CA2503471A1 (en) 2004-05-06
IS7851A (is) 2005-05-19

Similar Documents

Publication Publication Date Title
MA27524A1 (fr) Derives de 1-acyl-pyrrolidine destines au traitement d'infections virales
TNSN01102A1 (fr) Derives de pyrazole nouveaux, procede pour leur preparation et compositions les contenant.
TNSN98082A1 (fr) DERIVES SUBSTITUES EN C - 4 DE 9 - DESOXO - 9a - aza - 9a HOMOERYTHROMYCINE A.
NO20021528D0 (no) Kinuklidinforbindelser og medikamenter inneholdende de samme som den aktive bestanddel
NO20051411L (no) Pyrazolderivater, medisinske sammensetninger inneholdende slike, medisinsk bruk derav samt intermediater til fremstilling derav
TNSN98194A1 (fr) Derives nouveaux de 6-o-methylerythromycine a, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN00256A1 (fr) Inhibiteurs non peptidiques de la liaison cellulaire sous la dependance de vla-4 utiles dans le traitement des maladies inflammatoires, auto-immunes et respiratoires, et compositions les contenant
TNSN97023A1 (fr) Derives de triazole utiles en therapeutique, procedes pour leur preparation et compositions les contenant.
TNSN97197A1 (fr) Derives de pyrazole parasiticides, procede pour leur preparation et compositions les contenant.
TNSN01077A1 (fr) Derives de tropane nouveaux, procede pour leur preparation et compositions les contenant
CA2443449A1 (en) Pyrazole derivatives for treating hiv
TNSN07022A1 (fr) Derives de pyridine
MA27365A1 (fr) Derives de spiro-indolinepiperidine
EP1197210A4 (en) MEANS TO PREVENT THE CHRONIC BREATHING REACTION AS A RESULT OF AN ORGANTRANSPLANTATION
TNSN98083A1 (fr) Derives de 6-0 methylerythromycine a, procede pour leur preparation et compositions pharmaceutiques les contenant.
NO20040881L (no) Orale antidiabetes midler.
MA30014B1 (fr) Derives spirocycliques
TNSN99111A1 (fr) Derives de sulfonylbenzene nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant.
MA30904B1 (fr) Nouveaux derives du fluorene, compositions les contenant et utilisation comme inhibiteurs de la proteine chpaerone hsp90
DE3884555D1 (de) Octahydronaphthalenoxim-derivate fuer cholesterolsynthese-inhibierung, verfahren fuer deren herstellung und diese enthaltende zusammenstellungen.
GB0223232D0 (en) Chemical compounds
TNSN99146A1 (fr) Derives de 1-heteroaryl-pyrrolidine, -piperidine et - homopiperidine nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
MX2024014831A (es) Derivados de acido sialico y metodos de uso de los mismos
FR2756562B1 (fr) Nouveaux composes de n-benzenesulfonyl-l-proline, procede de preparation et utilisation en therapeutique
AU2003263455A1 (en) Pyrazole amides for treating hiv infections